Form 4: Neurocrine Biosciences CFO Matt Abernethy Reports Stock Transactions
SEC Form 4
Chief Financial Officer of Neurocrine Biosciences, Matt Abernethy, reports acquisition and disposition of common stock and derivative securities, including stock options and restricted stock units, through both market sales and vesting.
Summary
- Matt Abernethy, the CFO of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions from February 12, 2025, and February 13, 2025.
- Abernethy acquired shares through the vesting of stock options and restricted stock units (RSUs).
- He also disposed of shares through sales on the market, executed under Rule 10b5-1 trading plans.
- The sales were conducted at weighted average prices of $116.8487 and $116.8688 per share.
- Abernethy's holdings include common stock, stock options, and restricted stock units.
- The stock options vest monthly, and the RSUs vest annually over several years.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing is a routine disclosure of stock transactions by an executive. While stock sales can sometimes raise concerns, the presence of a 10b5-1 trading plan mitigates potential negative interpretations.
Positives
- The vesting of stock options and restricted stock units indicates a form of compensation and alignment with the company's long-term performance.
Negatives
- The sale of shares by the CFO, even under a pre-arranged trading plan, could be perceived negatively by some investors.
Risks
- Executive stock sales can sometimes be interpreted as a lack of confidence in the company's future prospects, although in this case, the sales are occurring under a pre-arranged 10b5-1 trading plan.
Future Outlook
The document details future vesting dates for stock options and restricted stock units, indicating ongoing equity-based compensation for the reporting person.
Industry Context
Executive stock transactions are common in the biopharmaceutical industry as part of compensation packages. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include stock options and restricted stock units to align management's interests with those of shareholders.
- Sales under 10b5-1 plans are a common practice to avoid accusations of insider trading, similar to practices at companies like Amgen (AMGN) and Gilead Sciences (GILD).
- The vesting schedules for RSUs, typically over 3-4 years, are standard practice, aligning with long-term performance goals, similar to those seen at Vertex Pharmaceuticals (VRTX).
Stakeholder Impact
- Shareholders may monitor these transactions for insights into executive sentiment and potential stock price impacts.
- Employees may view these transactions as part of the company's compensation structure.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Date of adoption of a Rule 10b5-1 trading plan by the Reporting Person. |
| February 13, 2023 | Date the RSU was granted to the Reporting Person. |
| June 14, 2024 | Date of adoption of a Rule 10b5-1 trading plan by the Reporting Person. |
| February 13, 2024 | Date the RSU award vested as to 2,566 shares. |
| February 12, 2025 | Date of stock option acquisition and RSU acquisition. |
| February 13, 2025 | Date of common stock transactions (acquisition and disposition). |
| March 12, 2025 | Date when 1/48th of the shares underlying the option becomes vested and exercisable. |
| February 12, 2026 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 13, 2026 | Date the RSU award will vest as to 2,566 shares. |
| February 12, 2027 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 13, 2027 | Date the RSU award will vest as to 2,566 shares. |
| February 12, 2028 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 13, 2028 | Date the RSU award will vest as to 2,566 shares. |
| February 12, 2029 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 12, 2035 | Expiration date of the stock options. |
Keywords
Form 4, Neurocrine Biosciences, NBIX, Matt Abernethy, CFO, Stock Options, Restricted Stock Units, Beneficial Ownership, SEC, 10b5-1 Trading Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.